SBRI Healthcare – AMR

Under the overall theme of “Antimicrobial resistance (AMR)”, Competition 25 Phase 1 invites early-stage innovations in the following four priority areas:

• Point of care diagnostics, monitoring, and susceptibility testing
• Prescribing decision support and risk stratification
• Novel care delivery methods
• Infection prevention and control (IPC)

Fund details

The competition is open to any innovation (e.g., medical device, in-vitro diagnostic, digital health solutions and AI solutions, behavioural interventions, and service improvements) that meets the entry criteria and the challenges described in the Challenge brief.

Eligibility 

Single organisations (contracts are executed with individual legal entities) based in the UK or EU from the private, public and third sectors, including companies (large corporates and small and medium enterprises), charities, universities, and NHS providers, given a strong commercial strategy is provided, are eligible to apply.

Organisations based outside the UK or EU with innovations in the remit for this call can apply as subcontractors of a lead UK/EU-based organisation or via a UK or EU subsidiary.

Collaborations are encouraged in the form of subcontracted services as appropriate.

At early stage, the SBRI Healthcare programme offers a two-phased development approach;

Phase 1 contracts for technical and commercial feasibility testing are valued at up to £100,000 (NET) and last for six months. If successful, Phase 1 projects are entitled to apply for Phase 2 contracts for prototype development and early clinical evidence which are usually worth up to £800,000 (NET) over 12 months, subject to budget availability.